More MS news articles for Aug 2001

Prevention of experimental autoimmune encephalomyelitis by encephalitogenic epitope sequence simplified derivatives.

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=11395134&dopt=Abstract

Mol Immunol 2001 Nov-Dec;37(16):951-60

Marino M, Ippolito A, Ruvo M, Scarallo A, Volpe S, Fassina G.

TECNOGEN S.C.p.A., Parco Scientifico, 81015 (CE), Piana di Monte Verna, Italy

The encephalitogenic epitope P81-100 from mouse myelin basic protein was used to generate two simplified derivatives with glycine substitutions in alternating positions which were tested for their biological activity in a murine model of multiple sclerosis, experimental autoimmune encephalomyelitis.

While both derivatives were unable to induce in mice the disease at the same parent peptide P81-100 dosage, T cell proliferation assays demonstrated their ability to compete with the parental peptide in a dose related manner.

Experiments of cell surface binding and T cell tolerance revealed a different behavior of the two derivatives, suggesting different roles in the MHC blockade or T cell tolerance.

On induction of encephalomyelitis in animals by P81-100 treatment, one variant proved in vivo to be very effective in protecting from the disease.

PMID: 11395134 [PubMed - in process]